Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.
BMJ Open Diabetes Res Care
; 8(2)2020 10.
Article
in En
| MEDLINE
| ID: mdl-33115821
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Diabetes Mellitus, Type 2
/
Glucagon-Like Peptide-1 Receptor
Limits:
Humans
Language:
En
Journal:
BMJ Open Diabetes Res Care
Year:
2020
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom